Emtricitabine, Tenofovir disoproxil and Rilpivirine is indicated for:
Population group: only adults (18 years old or older)
Emtricitabine/rilpivirine/tenofovir disoproxil combination is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤100,000 HIV-1 RNA copies/mL.
Genotypic resistance testing and/or historical resistance data should guide the use of emtricitabine/rilpivirine/tenofovir disoproxil.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Emtricitabine, Tenofovir disoproxil and Rilpivirine is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
